Nebenwirkungen · Rapiscan
Rapiscan 400 microgram solution for injection · Abschnitt 4.8 · PDF-Seite 6
HOS-122811 · Präparat HOS-095579
Summary of the safety profile Adverse reactions in most patients receiving regadenoson in clinical trials were mild, transient (usually resolving within 30 minutes after receiving regadenoson) and required no medical intervention. Adverse reactions occurred in approximately 80% of patients. The most common adverse reactions reported during clinical development in a total of 1,651 patients/subjects were: dyspnoea (29%), headache (27%), flushing (23%), chest pain (19%), electrocardiogram ST segment changes (18%), gastrointestinal discomfort (15%) and dizziness (11%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-03T01:00:00Z · SHA-256 87fa975fd0d5eb08a3954cff4145e271468e40268c84e21d2112c089fd88fe54 · Passage 7fc71e3edc1624d75b65955d763a5f2f0996bb4ac50a3b187c5621216142ed9e · Zeichen 0–571 im Abschnitt